Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, FDA Says
This article was originally published in The Pink Sheet Daily
Marketing exclusivity may be better way to go, FDA tells GAO, citing workload burdens and lack of evidence that vouchers have incentivized development of new treatments.
You may also be interested in...
Nancy Goodman, founder of Kids v Cancer, got two bills through Congress via PDUFA riders but struck out with Give Kids a Chance Act, which did not make it into the omnibus government funding legislation. She hopes to prevail next year.
US incentive program would gain only four more years, despite calls for a permanent extension.
Chair of the House Energy and Commerce Committee raises questions about the priority review voucher program’s value, suggesting another limited extension may be upcoming.